Author

Per Martin Hellström

INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEK SERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEK SERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE

THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH
THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH

EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE
EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE

THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH
THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH

Per Martin Hellström  et al.

INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEK SERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEK SERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE

Per Martin Hellström  et al.

EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE
EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE

Per Martin Hellström  et al.

CORRELATION BETWEEN GASTRIC EMPTYING PATTERNS, HUNGER AND SATIETY AS REGULATED BY GHRELIN AND GLUCAGON-LIKE PEPTIDE-1
CORRELATION BETWEEN GASTRIC EMPTYING PATTERNS, HUNGER AND SATIETY AS REGULATED BY GHRELIN AND GLUCAGON-LIKE PEPTIDE-1

Per Martin Hellström  et al.

GRANULOCYTE BIOMARKERS IN STOOL AND SERUM AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND LOCALIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GRANULOCYTE BIOMARKERS IN STOOL AND SERUM AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND LOCALIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Per Martin Hellström  et al.

EFFECTS OF FODMAPS AND GLUTEN ON IRRITABLE BOWEL SYNDROME - FROM SELF-REPORTED SYMPTOMS TO MOLECULAR PROFILING
EFFECTS OF FODMAPS AND GLUTEN ON IRRITABLE BOWEL SYNDROME - FROM SELF-REPORTED SYMPTOMS TO MOLECULAR PROFILING

Per Martin Hellström  et al.

PHARMACOKINETICS OF RECTALLY ADMINISTERED COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A PHASE IB OPEN-LABEL STUDY
PHARMACOKINETICS OF RECTALLY ADMINISTERED COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A PHASE IB OPEN-LABEL STUDY

Per Martin Hellström  et al.

HISTOPATHOLOGY BUT NOT MENTAL HEALTH ASSESSMENT DISTINGUISHES INDIVIDUALS WITH AND WITHOUT EROSIVE REFLUX DISEASE AND CONTROLS WITHOUT REFLUX DISEASE – A CROSS-SECTIONAL POPULATION-BASED STUDY
HISTOPATHOLOGY BUT NOT MENTAL HEALTH ASSESSMENT DISTINGUISHES INDIVIDUALS WITH AND WITHOUT EROSIVE REFLUX DISEASE AND CONTROLS WITHOUT REFLUX DISEASE – A CROSS-SECTIONAL POPULATION-BASED STUDY

Per Martin Hellström  et al.

Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders
Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders

Per Martin Hellström  et al.

GLP1 AND ANALOG ROSE-010 BIND GLP1 RECEPTOR AT AN NNOS-/FOX3+ SUBSET OF MYENTERIC NEURONS
GLP1 AND ANALOG ROSE-010 BIND GLP1 RECEPTOR AT AN NNOS-/FOX3+ SUBSET OF MYENTERIC NEURONS

Per Martin Hellström  et al.

Item 1 - 13 / 13
1